Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Klinische Wirksamkeit (39 Abbildungen)
Übersicht


Zum ersten Bild Abb. 32: Telmisartan - Losartan - HCTZ Abb. 33: Telmisartan - Losartan - HCTZ Abb. 34: Telmisartan - Valsartan - HCTZ Abb. 35: Telmisartan - HCTZ Aktuelles Bild - Abb. 36: Telmisartan - HCTZ Abb. 37: Telmisartan - HCTZ - Diabetes Abb. 38: Telmisartan - HCTZ Abb. 39: Telmisartan - HCTZ
Abbildung 36: Telmisartan - HCTZ
In a study comparing enalapril with telmisartan in the elderly, patients were given HCTZ 12.5–25 mg in addition to study medication if their response was insufficient (trough DBP ≥90 mmHg) after Week 12.1 In patients who received add-on HCTZ to telmisartan, SBP/DBP was significantly reduced. In a factorial study comparing different doses of telmisartan, HCTZ and the combination, the blood pressure response to telmisartan/HCTZ in elderly patients was similar to that in younger patients.2 SBP was reduced by 25.3 mmHg in elderly patients, compared with 23.5 mmHg in younger patients. In the ATHOS trial of elderly patients with ISH, 24-h mean reductions in SBP were greater with telmisartan/HCTZ than with amlodipine/HCTZ.3 1. Karlberg BE, et al. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999; 17: 293–302. 2. Fenton C, et al. Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension. Drugs 2003; 63: 2013–2026. 3. Data on file, Boehringer Ingelheim, GmBH.
 
Telmisartan - HCTZ
Vorheriges Bild Nächstes Bild   


Abbildung 36: Telmisartan - HCTZ
In a study comparing enalapril with telmisartan in the elderly, patients were given HCTZ 12.5–25 mg in addition to study medication if their response was insufficient (trough DBP ≥90 mmHg) after Week 12.1 In patients who received add-on HCTZ to telmisartan, SBP/DBP was significantly reduced. In a factorial study comparing different doses of telmisartan, HCTZ and the combination, the blood pressure response to telmisartan/HCTZ in elderly patients was similar to that in younger patients.2 SBP was reduced by 25.3 mmHg in elderly patients, compared with 23.5 mmHg in younger patients. In the ATHOS trial of elderly patients with ISH, 24-h mean reductions in SBP were greater with telmisartan/HCTZ than with amlodipine/HCTZ.3 1. Karlberg BE, et al. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999; 17: 293–302. 2. Fenton C, et al. Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension. Drugs 2003; 63: 2013–2026. 3. Data on file, Boehringer Ingelheim, GmBH.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung